Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up
Partnership Centers On TEV-56278, A Next-Generation Anti-PD1–IL2 Fusion Protein
Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w
